Keys to Unlock Cancer: Targeted Therapy

Carol Viele

ONF 2005, 32(5), 935-940. DOI: 10.1188/05.ONF.935-940

For decades, perhaps even centuries, researchers have searched for a cure for cancer. The effort has taken many approaches, from surgery to cytotoxic or cytostatic chemotherapy to radiation therapy to agents that alter the cellular microenvironment to preventive measures, such as nutrition, screening, and medications. The ultimate goal of each intervention has been to specifically affect the malignant cells, leaving normal cells intact. Unfortunately, this simple concept has been difficult to implement. The problem has been two-fold: first, identifying a unique property of malignant cells (target) and second, developing an agent that interacts solely with that property. Agents developed to interact with such targets are called targeted therapy. Epidermal growth factor receptors (EGFRs) and vascular endothelial growth factor (VEGF) are two such targets.

Jump to a section

    References

    D'Amato, R.J., Loughnan, M.S., Flynn, E., & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082-4085.

    Dvorak, H.F., Brown, L.F., Detmar, M., & Dvorak, A. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology, 146, 1029-1039.

    Ellis, L.M. (2004a). Angiogenesis and its role in colorectal tumor and metastasis formation. Seminars in Oncology, 31(6, Suppl. 17), 3-9.

    Ellis, L.M. (2004b). The biology of VEGF and tumor angiogenesis. Horizons in Cancer Therapeutics: From Bench to Bedside, 5, 4-10.

    Franson, P.J., & Lapka, D.V. (2005). Antivascular endothelial growth factor monoclonal antibody therapy: A promising paradigm in colorectal cancer. Clinical Journal of Oncology Nursing, 9, 55-60.

    Genentech, Inc. (2004). Avastin™ (bevacizumab). Retrieved March 20, 2005, from http://www.gene.com/gene/products/information/oncology/avastin Harari, P.M. (2004). Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer, 11, 689-708.

    Harari, P.M. (2004), Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer, 11, 689-708.

    Hicklin, D.J., & Ellis, L.M. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Clinical Oncology, 23, 1011-1027.

    Hoff, P.M. (2004). Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Seminars in Oncology, 31(6, Suppl. 17), 17-21.

    Hong, W., & Ullrich, A. (2000). Oncology biotherapeutics: The role of EGFR in solid tumors and implications for therapy. Retrieved July 25, 2005, from www.merck.es/oncologia/oncobio/oncobio_2001_voll_nol.pdf

    Ignoffo, R.J. (2004). Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. American Journal of Health-System Pharmacy, 61(21, Suppl. 5), S21-S26.

    Iqbal, S., & Lenz, H.J. (2004). Angiogenesis inhibitors in the treatment of colorectal cancer. Seminars in Oncology, 31(6, Suppl. 17), 10-16.

    Kohler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-497.

    Krozely, P. (2004). Epidermal growth factor receptor tyrosine kinase inhibitors: Evolving role in the treatment of solid tumors. Clinical Journal of Oncology Nursing, 8, 163-168.

    Kumar, S., Witzig, T.E., & Rajkumar, S.V. (2004). Thalidomid: Current role in the treatment of non-plasma cell malignancies. Journal of Clinical Oncology, 22, 2477-2488.

    Mendelsohn, J. (2001). The epidermal growth factor receptor as a target for cancer therapy. Endocrine-Related Cancer, 8, 3-9.

    Nicholson, R.I., Gee, J.M., & Harper, M.E. (2001). EGFR and cancer prognosis. European Journal of Cancer, 37(Suppl. 4), S9-S15.

    Pizzo, B. (2004). New directions in oncology nursing care: Focus on gefitinib in patients with lung cancer. Clinical Journal of Oncology Nursing, 8, 385-392.

    U.S. Food and Drug Administration. (2004). FDA statement on Iressa. Retrieved April 12, 2005, from http://www.fda.gov/bbs/topics/news/2004/new01145.html

    U.S. Food and Drug Administration. (2005a). Erbitux (cetuximab). Retrieved April 15, 2004, from http://www.fda.gov/cder/drug/infopage/erbitux/default.htm

    U.S. Food and Drug Administration. (2005b). Tarceva®. Retrieved April 24, 2005, from http://www.fda.gov/cder/consumerinfo/DRUGINFO/TARCEVA.htm

    Wells, A. (1999). EGF receptor. International Journal of Biochemistry and Cell Biology, 31, 637-643.

    Wilkes, G.M., & Barton-Burke, M. (Eds.). (2005). 2005 oncology nursing drug handbook. Sudbury, MA: Jones and Bartlett.

    Yarden, Y. (2001). The EGFR family and its ligands in human cancer: Signalling mechanisms and therapeutic opportunities. European Journal of Cancer, 37(Suppl. 4), S3-S8.